FLT3-ITD阳性急性髓系白血病免疫表型及临床特征分析

目的：探讨FLT3-ITD阳性急性髓系白血病的临床特征及免疫表型特点。方法回顾性分析我科2013年6月—2015年6月收治的FLT3-ITD阳性及FLT3-ITD阴性急性髓系白血病患者的免疫表型及实验室特点，对其进行分析总结，并结合相关文献复习展开讨论。结果 FLT3阳性急性髓系白血病患者CD117表达率显著低于FLT3阴性患者，CD33、CD56、CD7的表达率显著高于FLT3阴性患者；与FLT3阴性患者相比较， FLT3阳性患者外周血白细胞计数及骨髓白血病细胞比例显著增高，而血红蛋白含量及血小板计数差别无统计学意义；FLT3阳性患者治疗反应率（OR）显著低于FLT3阴性患者。结论 FLT3-ITD阳性急性髓系白血病患者白血病细胞抗原表达紊乱，高表达淋系抗原CD56、CD7及髓系抗原CD33，低表达髓系抗原CD117；FLT3阳性急性髓系白血病患者易合并外周血白细胞及骨髓白血病细胞高，完全缓解率低，是急性髓系白血病预后不良因素。

Analysis of Immunophenotype and Clinical Features in AML Patients with FLT3-ITD Positive

Objective To study the clinical features and immunophenotype of FMS-like tyrosine kinase 3 internal tandem duplica-tion (FLT3-ITD) positive acute myeloid leukemia (AML). Methods A retrospective study was made to immunophenotype and laborato-ry characteristics in AML patients with FLT3-ITD positive or negative hospitalized during the period from June, 2013 to June, 2015 and discussions on relevant literature was performed. Results The expression of CD117 in FLT3 positive AML patients was much lower than that in FLT3 negative AML patients while the expressions of CD33, CD56 and CD7 were much higher;the white blood cell count and bone marrow leukemia cells in FLT3 positive AML patients increased much more than those in FLT3 negative AML patients while there existed no statistical difference in hemoglobin and platelet count;The rate of treatment objective response (OR) in FLT3 positive AML patients was much lower than that in FLT3 negative AML patients. Conclusions The expression of leukemia cell antigen in FLT3-ITD positive AML is in disorder, the lymphoid lineage antigen CD56, CD7 and the myeloid antigen CD33 have high expression while the myeloid antigen CD117 has low expression;the FLT3 positive AML patients are prone to have the combination of high ratio of white blood cells and bone marrow leukemia cells, the complete remission rate is low and the prognosis of AML is poor.